Eiger BioPharmaceuticals to Participate in Investor Conferences in August
BTIG Biotechnology Conferenceat St. Regis Hotelin New York City. Eiger will host one-on-one meetings.
Wedbush PacGrow Healthcare Conferenceat Parker New York Hotelin New York City. Eiger will present a corporate update with a live webcast on August 13, 3:05-3:35 PM ET. Eiger will host one-on-one meetings.
The live webcast of the
Eiger is a late-stage biopharmaceutical company focused on the development and commercialization of a pipeline of first-in-class, well-characterized drugs for serious rare and ultra-rare diseases for patients with high unmet medical needs and for which no approved therapies exist.
The Company's lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection. The company is also advancing peginterferon lambda, a first-in-class interferon, toward a Phase 3 study for the treatment of HDV. Eiger is preparing an NDA and MAA for lonafarnib to treat Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies with plans to file in 2019. For additional information about Eiger and its clinical programs, please visit www.eigerbio.com.
View original content to download multimedia:http://www.prnewswire.com/news-releases/eiger-biopharmaceuticals-to-participate-in-investor-conferences-in-august-300896089.html